Adaptive Biotechnologies (ADPT) Receivables (2018 - 2026)

Adaptive Biotechnologies (ADPT) has 9 years of Receivables data on file, last reported at $49.9 million in Q1 2026.

• Quarterly Receivables rose 10.72% year-over-year to $49.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $49.9 million (up 10.72% YoY) and the FY2025 annual result came in at $51.9 million, up 20.53% from the prior year.
• Receivables fell to $49.9 million in Q1 2026 per ADPT's latest filing, from $51.9 million in the prior quarter.
• The five-year high for Receivables was $51.9 million in Q4 2025, with the low at $23.6 million in Q1 2022.
• Average Receivables over 5 years is $38.6 million, with a median of $40.9 million recorded in 2022.
• Year-over-year, Receivables surged 117.22% in 2022 and dropped 4.62% in 2023.
• Adaptive Biotechnologies' Receivables stood at $40.9 million in 2022, then retreated by 4.62% to $39.0 million in 2023, then climbed by 10.42% to $43.0 million in 2024, then increased by 20.53% to $51.9 million in 2025, then declined by 3.76% to $49.9 million in 2026.
• Business Quant data shows ADPT's Receivables at $49.9 million in Q1 2026, $51.9 million in Q4 2025, and $46.3 million in Q3 2025.